{
    "id": 22985,
    "fullName": "TNFRSF8 positive",
    "impact": "unknown",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "TNFRSF8 positive indicates the presence of the TNFRSF8 gene, mRNA, and/or protein.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 943,
        "geneSymbol": "TNFRSF8",
        "terms": [
            "TNFRSF8",
            "CD30",
            "D1S166E",
            "Ki-1"
        ]
    },
    "variant": "positive",
    "createDate": "05/27/2016",
    "updateDate": "07/21/2017",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 18894,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Adcentris (brentuximab vedotin) is included in guidelines as a preferred second-line and subsequent therapy for patients with TNFRSF8 (CD30)-positive peripheral T-cell lymphoma (NCCN.org).",
            "molecularProfile": {
                "id": 23635,
                "profileName": "TNFRSF8 positive"
            },
            "therapy": {
                "id": 2486,
                "therapyName": "Brentuximab vedotin",
                "synonyms": null
            },
            "indication": {
                "id": 50749,
                "name": "peripheral T-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 18893,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Adcentris (brentuximab vedotin) in combination with cyclophosphamide, doxorubicin, and prednisone (CHP) is included in guidelines as preferred first-line therapy for patients with TNFRSF8 (CD30)-positive angioimmunoblastic T-cell lymphoma (NCCN.org).",
            "molecularProfile": {
                "id": 23635,
                "profileName": "TNFRSF8 positive"
            },
            "therapy": {
                "id": 7500,
                "therapyName": "Brentuximab vedotin + Cyclophosphamide + Doxorubicin + Prednisone",
                "synonyms": null
            },
            "indication": {
                "id": 111147,
                "name": "angioimmunoblastic T-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 16919,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (ECHELON-2) that supported FDA approval, treatment with Adcentris (brentuximab vedotin) in combination with cyclophosphamide, doxorubicin, and prednisone (CHP) resulted in improved median progression-free survival (48.2 vs 20.8 months, HR=0.71, p=0.011) compared to standard chemotherapy in patients with previously untreated TNFRSF8 (CD30)-positive peripheral T-cell lymphoma, including angioimmunoblastic T-cell lymphoma (PMID: 30522922; NCT01777152).",
            "molecularProfile": {
                "id": 23635,
                "profileName": "TNFRSF8 positive"
            },
            "therapy": {
                "id": 7500,
                "therapyName": "Brentuximab vedotin + Cyclophosphamide + Doxorubicin + Prednisone",
                "synonyms": null
            },
            "indication": {
                "id": 111147,
                "name": "angioimmunoblastic T-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15061,
                    "pubMedId": 30522922,
                    "title": "Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30522922"
                },
                {
                    "id": 15574,
                    "pubMedId": null,
                    "title": "Adcetris (brentuximab vedotin) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125388"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 16918,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (ALCANZA) that supported FDA approval, Adcetris (brentuximab vedotin) treatment resulted in an objective response lasting at least 4 months in 56.3% (36/64) of patients with previously treated TNFRSF8-positive mycosis fungoides (n=48) or primary cutaneous anaplastic large-cell lymphoma (n=16) (PMID: 28600132; NCT01578499).",
            "molecularProfile": {
                "id": 23635,
                "profileName": "TNFRSF8 positive"
            },
            "therapy": {
                "id": 2486,
                "therapyName": "Brentuximab vedotin",
                "synonyms": null
            },
            "indication": {
                "id": 50744,
                "name": "anaplastic large cell lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10386,
                    "pubMedId": 28600132,
                    "title": "Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28600132"
                },
                {
                    "id": 15574,
                    "pubMedId": null,
                    "title": "Adcetris (brentuximab vedotin) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125388"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 19122,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Adcentris (brentuximab vedotin) is included in guidelines as a second-line and subsequent therapy for patients with TNFRSF8 (CD30)-positive diffuse large B-cell lymphoma (NCCN.org).",
            "molecularProfile": {
                "id": 23635,
                "profileName": "TNFRSF8 positive"
            },
            "therapy": {
                "id": 1231,
                "therapyName": "Bendamustine",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 15229,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (ECHELON-2) that supported FDA approval, treatment with Adcentris (brentuximab vedotin) in combination with cyclophosphamide, doxorubicin, and prednisone (CHP) resulted in improved median progression-free survival (48.2 vs 20.8 months, HR=0.71, p=0.011) compared to standard chemotherapy in patients with previously untreated TNFRSF8 (CD30)-positive peripheral T-cell lymphoma, 75% of the patients were diagnosed with systemic anaplastic large cell lymphoma (PMID: 30522922; NCT01777152).",
            "molecularProfile": {
                "id": 23635,
                "profileName": "TNFRSF8 positive"
            },
            "therapy": {
                "id": 7500,
                "therapyName": "Brentuximab vedotin + Cyclophosphamide + Doxorubicin + Prednisone",
                "synonyms": null
            },
            "indication": {
                "id": 50744,
                "name": "anaplastic large cell lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15061,
                    "pubMedId": 30522922,
                    "title": "Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30522922"
                },
                {
                    "id": 15574,
                    "pubMedId": null,
                    "title": "Adcetris (brentuximab vedotin) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125388"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 18892,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Adcentris (brentuximab vedotin) in combination with cyclophosphamide, doxorubicin, and prednisone (CHP) is included in guidelines as preferred first-line therapy and subsequent therapy for patients with TNFRSF8 (CD30)-positive peripheral T-cell lymphoma (NCCN.org).",
            "molecularProfile": {
                "id": 23635,
                "profileName": "TNFRSF8 positive"
            },
            "therapy": {
                "id": 7500,
                "therapyName": "Brentuximab vedotin + Cyclophosphamide + Doxorubicin + Prednisone",
                "synonyms": null
            },
            "indication": {
                "id": 50749,
                "name": "peripheral T-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 15228,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (ECHELON-2) that supported FDA approval, treatment with Adcentris (brentuximab vedotin) in combination with cyclophosphamide, doxorubicin, and prednisone (CHP) resulted in improved median progression-free survival (48.2 vs 20.8 months, HR=0.71, p=0.011) compared to standard chemotherapy in patients with previously untreated TNFRSF8 (CD30)-positive peripheral T-cell lymphoma, 75% of the patients were diagnosed with systemic anaplastic large cell lymphoma (PMID: 30522922; NCT01777152).",
            "molecularProfile": {
                "id": 23635,
                "profileName": "TNFRSF8 positive"
            },
            "therapy": {
                "id": 7500,
                "therapyName": "Brentuximab vedotin + Cyclophosphamide + Doxorubicin + Prednisone",
                "synonyms": null
            },
            "indication": {
                "id": 50749,
                "name": "peripheral T-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15061,
                    "pubMedId": 30522922,
                    "title": "Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30522922"
                },
                {
                    "id": 15574,
                    "pubMedId": null,
                    "title": "Adcetris (brentuximab vedotin) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125388"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 9559,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (ALCANZA) that supported FDA approval, Adcetris (brentuximab vedotin) treatment resulted in an objective response lasting at least 4 months in 56.3% (36/64) of patients with previously treated TNFRSF8-positive mycosis fungoides (n=48) or primary cutaneous anaplastic large-cell lymphoma (n=16) (PMID: 28600132; NCT01578499).",
            "molecularProfile": {
                "id": 23635,
                "profileName": "TNFRSF8 positive"
            },
            "therapy": {
                "id": 2486,
                "therapyName": "Brentuximab vedotin",
                "synonyms": null
            },
            "indication": {
                "id": 8691,
                "name": "mycosis fungoides",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10386,
                    "pubMedId": 28600132,
                    "title": "Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28600132"
                },
                {
                    "id": 15574,
                    "pubMedId": null,
                    "title": "Adcetris (brentuximab vedotin) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125388"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 18960,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Adcentris (brentuximab vedotin) is included in guidelines as a second-line or subsequent therapy for patients with TNFRSF8 (CD30)-positive adult T-cell leukemia/lymphoma (NCCN.org).",
            "molecularProfile": {
                "id": 23635,
                "profileName": "TNFRSF8 positive"
            },
            "therapy": {
                "id": 2486,
                "therapyName": "Brentuximab vedotin",
                "synonyms": null
            },
            "indication": {
                "id": 50523,
                "name": "adult T-cell leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 18959,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Adcentris (brentuximab vedotin) in combination with cyclophosphamide, doxorubicin, and prednisone (CHP) is included in guidelines as an initial therapy for patients with TNFRSF8 (CD30)-positive adult T-cell leukemia/lymphoma (NCCN.org).",
            "molecularProfile": {
                "id": 23635,
                "profileName": "TNFRSF8 positive"
            },
            "therapy": {
                "id": 7500,
                "therapyName": "Brentuximab vedotin + Cyclophosphamide + Doxorubicin + Prednisone",
                "synonyms": null
            },
            "indication": {
                "id": 50523,
                "name": "adult T-cell leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 18895,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Adcentris (brentuximab vedotin) is included in guidelines as a preferred second-line and subsequent therapy for patients with TNFRSF8 (CD30)-positive angioimmunoblastic T-cell lymphoma (NCCN.org).",
            "molecularProfile": {
                "id": 23635,
                "profileName": "TNFRSF8 positive"
            },
            "therapy": {
                "id": 2486,
                "therapyName": "Brentuximab vedotin",
                "synonyms": null
            },
            "indication": {
                "id": 111147,
                "name": "angioimmunoblastic T-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        }
    ],
    "molecularProfiles": [
        {
            "id": 23635,
            "profileName": "TNFRSF8 positive",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}